Hand Rehabilitation Using Botulinum Toxin and Functional Electrical Stimulation-pilot Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03549975 |
Recruitment Status :
Completed
First Posted : June 8, 2018
Last Update Posted : June 8, 2018
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Stroke Spastic Hemiparesis Spasticity as Sequela of Stroke | Drug: Botulinum Toxin Type A 100 unit/Vial (Product) | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 20 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Hand Rehabilitation Using Botulinum Toxin and Functional Electrical Stimulation Among Stroke Patients With Limitation of Finger Extension Due to Spasticity- Pilot Study |
Actual Study Start Date : | May 18, 2016 |
Actual Primary Completion Date : | August 18, 2017 |
Actual Study Completion Date : | August 18, 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: Botulinum toxin type A injection
Botulinum toxin type A injection followed by functional electrical stimulation
|
Drug: Botulinum Toxin Type A 100 unit/Vial (Product)
Botulinum toxin type A injection followed by functional electrical stimulation
Other Name: functional electrical stimulation |
- Change in Box and Block test [ Time Frame: baseline, 2 weeks after baseline, 6 weeks after baseline, 10 weeks after baseline ]number of box moved by affected upper extremity
- Change of Action Research Arm Test [ Time Frame: baseline, 2 weeks after baseline, 6 weeks after baseline, 10 weeks after baseline ]Score of Action Research Arm Test
- Muscle strength of finger extensor [ Time Frame: baseline, 2 weeks after baseline, 6 weeks after baseline, 10 weeks after baseline ]Medical research council grading of muscle strength
- Spasticity of finger extensor [ Time Frame: baseline, 2 weeks after baseline, 6 weeks after baseline, 10 weeks after baseline ]Modified ashworth scale of finger flexor
- active range of motion of wrist joint [ Time Frame: baseline, 2 weeks after baseline, 6 weeks after baseline, 10 weeks after baseline ]active range of motion of wrist joint
- Brunnstrom stage of stroke recovery of distal upper extremity [ Time Frame: baseline, 2 weeks after baseline, 6 weeks after baseline, 10 weeks after baseline ]Brunnstrom stage of stroke recovery of distal upper extremity. By observing the pattern of participants posture, the stage was scored. The stage ranges from 1 to 6. Higher is better.
- Distance from middle finger tip to mid-palmar crease [ Time Frame: baseline, 2 weeks after baseline, 6 weeks after baseline, 10 weeks after baseline ]Distance from middle finger tip to mid-palmar crease
- Repeated number of finger extension and flexion [ Time Frame: baseline, 2 weeks after baseline, 6 weeks after baseline, 10 weeks after baseline ]Repeated number of finger extension and flexion
- Quick Disabilities of Arm, Shoulder & Hand [ Time Frame: baseline, 2 weeks after baseline, 6 weeks after baseline, 10 weeks after baseline ]
Quick Disabilities of Arm, Shoulder & Hand is questionnaire about patients' symptoms as well as ability to perform certain activities in the last week.
Total score is obtained by summing the each question, and ranges from 0 (no disability) to 100 (most severe disability).
- Grading of active thumb opposition [ Time Frame: baseline, 2 weeks after baseline, 6 weeks after baseline, 10 weeks after baseline ]Grading of active thumb opposition. It is measured by observing the pattern of thumb opposition.
- Grip strength [ Time Frame: baseline, 2 weeks after baseline, 6 weeks after baseline, 10 weeks after baseline ]measured by Jamar dynamometer
- Active finger extension [ Time Frame: baseline, 2 weeks after baseline, 6 weeks after baseline, 10 weeks after baseline ]Active finger extension. It is graded by observation of voluntary finger extension.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 19 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- age over 18 years
- hemiplegic upper limb spasticity secondary to a unilateral ischemic or hemorrhagic stroke
- fingers and wrist flexor spasticity graded at least 1+ on the Modified Ashworth Scale
- at least 6 months since stroke
Exclusion Criteria:
- fixed contracture
- previous treatment of the upper limb spasticity with neurolytic or surgical procedure
- treatment with botulinum toxin type A in the previous 4 months
- any active device implant
- any neurological disorder, other than stroke causing motor deficits or spasticity
- inability to attend to and/or to cooperate with all outcome measure-related task secondary to cognitive impairment or aphasia
- pregnancy, planned pregnancy, or lactation
- contraindication to botulinum toxin type A

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03549975
Principal Investigator: | Joon-Ho Shin, MS | National Rehabilitation Center of Korea |
Responsible Party: | Joon-Ho Shin, Team manager of Department of Neurorehabilitation, National Rehabilitation Center, Seoul, Korea |
ClinicalTrials.gov Identifier: | NCT03549975 |
Other Study ID Numbers: |
NRC-2016-02-011 |
First Posted: | June 8, 2018 Key Record Dates |
Last Update Posted: | June 8, 2018 |
Last Verified: | May 2018 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
stroke hand botulinum toxin functional electrical stimulation |
Muscle Spasticity Stroke Paresis Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases Muscular Diseases Musculoskeletal Diseases Muscle Hypertonia Neuromuscular Manifestations |
Neurologic Manifestations Botulinum Toxins Botulinum Toxins, Type A abobotulinumtoxinA Acetylcholine Release Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Cholinergic Agents Neurotransmitter Agents Physiological Effects of Drugs Neuromuscular Agents Peripheral Nervous System Agents |